title: Effects of cilostazol on lipid and fatty acid metabolism.
abstract: Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. Randomised, double-blind, placebo-controlled trials in 2702 patients with intermittent claudication demonstrated that cilostazol significantly increased walking distances compared with placebo. Furthermore, the agent has beneficial effects on the serum lipid profile and fatty acid composition in plasma. Consequently, cilostazol may be useful to prevent atherosclerosis from progressing by ameliorating lipid and fatty acid metabolism.
authors.affiliation: The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki-city, Aomori 036-8562, Japan. nnakamur-tym@umin.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Osawa
authors.forename: H
authors.initials: H
authors.lastname: Yamabe
authors.forename: K
authors.initials: K
authors.lastname: Okumura
authors.forename: T
authors.initials: T
authors.lastname: Hamazaki
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000188:drug therapy*; D000077407:Cilostazol; D004311:Double-Blind Method; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005227:Fatty Acids; D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol